Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

被引：5
|
作者：
Ishak, K. Jack [1 ]
Rael, Michael [2 ]
Hicks, Meagen [3 ]
Mittal, Sangeeta [3 ]
Eatock, Martin [4 ]
Valle, Juan W. [5 ,6 ]
机构：
[1] Evidera Inc, Montreal, PQ, Canada
[2] Evidera Inc, San Francisco, CA 94111 USA
[3] Pfizer Ltd, Walton Oaks, Surrey, England
[4] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland
[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 10期
关键词：
comparative effectiveness; everolimus; MAIC; matching-adjusted indirect comparison; sunitinib;
D O I：
10.2217/cer-2018-0020
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus. Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS. Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.
引用
收藏
页码：947 / 958
页数：12
相关论文
共 50 条
  • [1] Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison
    Signorovitch J.
    Swallow E.
    Kantor E.
    Wang X.
    Klimovsky J.
    Haas T.
    Devine B.
    Metrakos P.
    Experimental Hematology & Oncology, 2 (1)
  • [2] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Betts, Keith A.
    Mittal, Manish
    Song, Jinlin
    Skup, Martha
    Joshi, Avani
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 349 - 362
  • [3] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Vibeke Strand
    Keith A. Betts
    Manish Mittal
    Jinlin Song
    Martha Skup
    Avani Joshi
    Rheumatology and Therapy, 2017, 4 : 349 - 362
  • [4] Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
    Maksymowych, Walter P.
    Strand, Vibeke
    Nash, Peter
    Yazici, Yusuf
    Thom, Howard
    Hunger, Matthias
    Kalyvas, Chrysostomos
    Gandhi, Kunal K.
    Porter, Brian
    Jugl, Steffen M.
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2018, 5 (04) : 216 - +
  • [5] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 99 - 122
  • [6] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    Rheumatology and Therapy, 2018, 5 : 99 - 122
  • [7] A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons
    Cassidy, Owen
    Harte, Marie
    Trela-Larsen, Lea
    Walsh, Cathal
    White, Arthur
    McCullagh, Laura
    Leahy, Joy
    VALUE IN HEALTH, 2023, 26 (11) : 1665 - 1674
  • [8] A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Suarez, Cristina
    Bourlon, Maria T.
    Barata, Pedro C.
    Gulati, Shuchi
    Huo, Stephen
    Ejzykowicz, Flavia
    Blum, Steven I.
    Del Tejo, Viviana
    Hamilton, Melissa
    May, Jessica R.
    Du, Ella X.
    Wu, Aozhou
    Kral, Pavol
    Ivanescu, Cristina
    Chin, Andi
    Betts, Keith A.
    Lee, Chung-Han
    Choueiri, Toni K.
    Cella, David
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 339 - 348
  • [9] Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
    Irina Proskorovsky
    Agnes Benedict
    Sylvie Negrier
    Danielle Bargo
    Rickard Sandin
    Krishnan Ramaswamy
    Jigar Desai
    Joseph C. Cappelleri
    James Larkin
    BMC Cancer, 18
  • [10] Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
    Proskorovsky, Irina
    Benedict, Agnes
    Negrier, Sylvie
    Bargo, Danielle
    Sandin, Rickard
    Ramaswamy, Krishnan
    Desai, Jigar
    Cappelleri, Joseph C.
    Larkin, James
    BMC CANCER, 2018, 18
12345